Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.
Jupiter Endovascular has treated the first two patients in the SPIRARE I study, utilising its Vertex pulmonary embolectomy ...
Robert W. Baird has recently initiated Vertex Inc (VERX) stock to Outperform rating, as announced on July 23, 2024, according to Finviz. Earlier, on March 1, 2024, BofA Securities had raised the stock ...